Kengreal Generic Name & Formulations
Cangrelor 50mg/vial; lyophilized pwd for IV inj after reconstitution and dilution; contains mannitol, sorbitol.
P2Y12 platelet inhibitor (ATP analog).
Single-use vial (10mL)—1, 10
As adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Kengreal Dosage and Administration
Initially 30mcg/kg IV bolus prior to PCI, followed immediately by 4mcg/kg/min IV infusion; continue infusion for ≥2hrs or for duration of PCI, whichever is longer. Transitioning to oral P2Y12 therapy: see full labeling.
Significant active bleeding.
Kengreal Boxed Warnings
Increased risk of bleeding. Discontinue 1hr prior to labor, delivery or neuraxial blockade. Pregnancy. Nursing mothers.
Administer clopidogrel or prasugrel after infusion is discontinued.
Kengreal Adverse Reactions
Bleeding, renal impairment, dyspnea, hypersensitivity reactions.
Kengreal Clinical Trials
Kengreal Patient Counseling